Metformina Hexal

Metformin, the active ingredient in Metformina Hexal, is a biguanide presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels by improving the body’s response to insulin and decreasing hepatic glucose output.

GNH USA supplies Metformina Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Hexal, a biguanide antidiabetic, acts on glucose metabolism pathways to control hyperglycaemia. - Type 2 diabetes mellitus: improves glycaemic control and reduces fasting plasma glucose. - Gestational diabetes mellitus: helps maintain target glucose levels during pregnancy. - Prediabetes (impaired glucose tolerance): may delay progression to overt diabetes when combined with lifestyle measures.

Metformina Hexal may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare but serious events require prompt medical attention.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term use may impair absorption. - Acute pancreatitis: rare inflammatory condition of the pancreas.

Before initiating Metformina Hexal, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function assessment: ensure adequate kidney clearance before starting and periodically thereafter. - Hepatic status review: avoid use in patients with significant liver disease. - Lactic acidosis risk: contraindicate in conditions predisposing to hypoxia or severe infection. - Elderly dosing: consider lower starting dose and close monitoring. - Alcohol consumption: advise patients to limit alcohol to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Hexal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise plasma metformin concentrations, enhancing toxicity. - Alcohol: synergistic effect on lactic acidosis development.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics (loop or thiazide): can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may impair renal function, increasing metformin exposure. - Calcium channel blockers: occasional reports of altered glucose control.